Cancer Res Treat.  2025 Jan;57(1):289-290. 10.4143/crt.2024.779.

Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”

• Topkan E
• Somay E
• Durankus NK
• Selek U

• KMID: 2564601
• DOI: http://doi.org/10.4143/crt.2024.779

Reference

References

1. Yu YF, Wu P, Zhuo R, Wu SG. Metronomic S-1 adjuvant chemotherapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treat. 2024; 56:1058–67.

2. Prinja S, Gupta N, Verma R. Censoring in clinical trials: review of survival analysis techniques. Indian J Community Med. 2010; 35:217–21.

3. Delgado A, Guddati AK. Clinical endpoints in oncology: a primer. Am J Cancer Res. 2021; 11:1121–31.

4. Xiang L, Rong JF, Xin C, Li XY, Zheng Y, Ren PR, et al. Reducing target volumes of intensity modulated radiation therapy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of a prospective, multicenter, randomized trial. Int J Radiat Oncol Biol Phys. 2023; 117:914–24.

5. Yildirim HC, Kupik GE, Mustafayev TZ, Berber T, Yavuz B, Cetinayak O, et al. A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001). Head Neck. 2023; 45:1194–205.